Pell Bio-Med Technology Co., Ltd.
2 clinical trials · Sponsor
◉ Watch Pell Bio-Med Technology Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy (NCT05377307) | Pell Bio-Med Technology Co., Ltd. | 2022-12-29 |
| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma (NCT05326243) | Pell Bio-Med Technology Co., Ltd. | 2022-05-31 |
Track Pell Bio-Med Technology Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.